Condom efficacy
This article was originally published in The Gray Sheet
Executive Summary
Latex condoms are "highly effective for preventing HIV infection and other [sexually transmitted diseases] when used consistently and correctly," the Centers for Disease Control and Prevention concludes in the Aug. 6 Morbidity and Mortality Weekly Report. CDC cites two studies of condom use among HIV serodiscordant heterosexual couples. In one study, "none of 123 partners who used condoms consistently seroconverted," while 12 (10%) of 122 seronegative partners who use condoms inconsistently seroconverted. In the second study, three (2%) of 171 consistent condom users seroconverted, compared with eight (15%) of 55 inconsistent condom users. In addition, "three prospective studies in developed countries indicated that condoms are unlikely to break or slip during proper use," CDC says.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.